1 Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells 2 and Age.

3

Amelie E. Murrell^{1,12}; Ewono Eyoh^{1,12}; Jeffrey G. Shaffer²; Monika L. Dietrich^{3,4}; Ivy V. Trinh¹;
Thomas J. Yockachonis⁶; Shuangyi Bai⁶; Crystal Y. Zheng⁷; Celia V. Mayne⁴; Sofia E. Cabrera³;
Anyssa Aviles-Amaro¹; Addison E. Stone¹; Saraswatie Rambaran¹; Sruti Chandra³; Debra H.
Elliott³; Ashley R. Smira³; Sara N. Harris³; Katharine E. Olson³; Samantha J. Bilton¹; Medea J.
Gabriel³; Nicole D. Falgout³; Emily J. Engel³; Alisha D. Prystowsky³; Bo Ning^{8,9}; Tony Hu^{8,9}; Jay
K. Kolls^{3,10}, Samuel J. Landry⁹, Stacy S. Drury^{3,4,5}; John S. Schieffelin^{3,4}; Kevin J. Zwezdaryk^{1,11};

- James E. Robinson^{3,4}; Bronwyn M. Gunn^{6,13}; Elizabeth B. Norton^{1,11,13*}
- 11
- ¹Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans,
 LA
- ²Department of Biostatistics & Data Science, School of Public Health and Tropical Medicine,
 Tulane University, New Orleans, LA
- 16 ³Department of Pediatrics, Tulane University School of Medicine, New Orleans LA
- ¹⁰ ¹Department of Child Develotry, Tulone University School of Medicine, New Orleans LA
- ⁴Department of Child Psychiatry, Tulane University School of Medicine, New Orleans LA
- 18 ⁵Children's Hospital New Orleans, New Orleans, LA
- 19 ⁶Paul G. Allen School of Global Health, Washington State University, WA
- ⁷ Department of Medicine, Section of Infectious Diseases, Tulane University School of Medicine,
- 21 New Orleans LA
- ⁸Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New
 Orleans, LA
- ⁹Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New
 Orleans, LA
- ¹⁰Center for Translational Research in Infection and Inflammation, Tulane University School of
 Medicine, New Orleans, LA
- ¹¹Tulane Center for Aging, Tulane University School of Medicine, New Orleans, LA
- 29 ¹²These authors contributed equally to this work
- 30 ¹³These authors contributed equally to this work
- 31
- 32 * Correspondence: enorton@tulane.edu
- 33 34

35 SUMMARY

- 36 SARS-CoV-2 infection causes a spectrum of clinical outcomes and diverse memory responses.
- 37 Population studies indicate that viral neutralizing antibody responses are protective, but do not
- 38 always develop post-infection. Other antiviral antibody effector functions, T-cell responses, or
- immunity to seasonal coronaviruses (OC43, 229E) have been implicated but not defined in all
- 40 ages. Here, we identify that children and adult subjects generate polyfunctional antibodies to the
- 41 spike protein after asymptomatic infection or mild disease, with some subjects developing
- 42 cellular responses without seroconversion. Diversity in immunity was explained by two clusters
- 43 distinguished by CD4+ T-cell cytokines, age, and antibodies to seasonal coronaviruses. Post-
- 44 vaccination neutralizing responses were predicted by specific post-infection immune measures,
- 45 including IL-2, spike-IgA, OC43-IgG1, 229E-IgM. We confirm a key role for CD4+ T cell
- 46 cytokines in functionality of anti-spike antibodies, and show that antibody diversity is impacted
- by age, Th/Th2 cytokine biases, and antibody isotypes to SARS-CoV-2 and seasonal
 coronaviruses.

49 INTRODUCTION

50 Since the start of the coronavirus disease pandemic in 2019 (COVID-19), a central question is 51 what characterizes protective immune responses to the SARS-CoV-2 virus. The risk of SARS-52 CoV-2 reinfection is estimated as 0–19.5% for at least 10 months following primary infection, 53 indicating that some level of protective immunity develops after infection [1]. Human [2-5] and 54 animal studies [6, 7] have shown that B-cells, antibodies, CD4+ and CD8+ T-cells play essential 55 roles in protection and memory responses. The quality and quantity of these responses are likely 56 key to long-term protective immunity, yet the underlying mechanisms driving these immune 57 responses are still unclear.

58 Age is a major driver of disease outcomes and significantly impacts the severity and development 59 of SARS-CoV-immunity [8-14]. Children develop functional cellular and humoral immunity to 60 infection but are more likely to be asymptomatic or exhibit mild COVID-19 than adults [8, 10, 15]. 61 Increased age, disease severity, and male sex have all been linked to the development of higher levels of viral-specific IgG and neutralizing antibodies post-infection [16-18]. Population-based 62 63 studies have shown a central role for these neutralizing antibodies in infection and vaccine-64 mediated protection to SARS-CoV-2 viral strains [19-21]. Yet, antibody responses exhibit 65 significant variation by subject, and specific protective antibody levels or tests have yet to be 66 identified [22]. In addition, several studies have shown that antibodies with polyfunctional activities 67 that neutralize viral entry and recruit innate immune effector functions, such as complement 68 deposition, neutrophil, and monocyte phagocytosis, and Natural Killer (NK) cell activation, are 69 inversely correlated with disease severity following infection [10, 19, 20, 23]. These reports 70 indicate diversity in SARS-CoV-2 humoral immunity suggesting that the qualitative features of 71 antibodies are likely just as important as titers and neutralizing responses.

72 T-cell responses also develop early post-infection and are sustained over time. CD4+ T-cell 73 responses are typically characterized by a type 1 phenotype (Th1), with expression of IL-2, IFNy, 74 and TNFa that are induced early during SARS-CoV-2 infection with a prolonged contraction in 75 patients with severe or mild disease [4, 24-28]. Higher Th1 cell responses have been reported in 76 asymptomatic versus symptomatic patients, but the latter also express more inflammatory 77 cytokines (IL-1 β , IL-6, TNF α) [24]. Interestingly, while T-cell responses are linked to the 78 development of antibody responses [3], they are also detected in some people who never 79 developed viral-specific antibodies; a phenomenon termed cellular sensitization without 80 seroconversion [26] that has also been observed with other coronaviruses [29]. CD8+ T-cells have been linked to viral clearance [30, 31], but others have suggested this early control of viremia 81 82 is from bystander CD8+ T-cells activation and innate immunity [26, 32]. Taken together, these 83 studies indicate SARS-CoV-2-specific CD4+ and CD8+ T-cell responses following infection also 84 vary in magnitude across individuals, but their importance is debated.

Thus, factors contributing to the diversity of SARS-CoV-2 immunity are poorly understood. Notably, most COVID-19 studies have focused on immunity generated following severe infection in hospitalized patients, reflecting less than 10% of infected individuals in the United States. Additional limitations of existing studies include inadequate representation of all age groups for non-severe infections and a focus on antibody effector functions or T-cell immunity, but rarely both. The objective of this study was to address these knowledge gaps by integrating a systems serology approach with T-cell and cytokine measures to generate a comprehensive evaluation of

post-infection immunity and longevity. To do so, we compared immune responses as a function
of age (1–79 years) in a cohort of infected, non-hospitalized versus non-infected subjects
spanning pre- and post-COVID-19 and vaccination periods.

- 95
- 96
- 97

98 **RESULTS**:

99 Demographics of the Community Seroepidemiology and Immunity (CSI) cohort and 100 symptoms experienced across cohort subjects and households.

We recruited a cohort of 91 individuals from 45 households located in Greater New Orleans, Louisiana, community from June 2020 to March 2021 (**Table 1**). Subjects self-reported with suspected or confirmed SARS-CoV-2 infection or exposure between March 2020 and December 2020 before the circulation of Delta or Omicron variants. Each participant completed a survey that collected parameters of demographics, history of infection or exposure, and clinical signs and symptoms (**Table S1**). Importantly, none of the participants had been hospitalized for infection, although ten subjects reported visiting the emergency room for their illness.

- SARS-CoV-2 infection in 67 subjects (74%) was confirmed either by a PCR test (n=42), SARS-CoV-2 spike or nucleoprotein specific IgG by ELISA and Luminex testing (54 and 32 subjects, respectively) or viral RNA detection in plasma (n=11) by a sensitive CRISPR assay [33, 34]. The remaining 24 subjects exhibited no evidence of SARS-CoV-2 infection. Blood samples were collected at a range of times post-symptom onset or days post-exposure (**Figure 1A**) (range of
- 113 10–289 days; median of 99 days from subjects), and subjects exhibited a range of disease
- severity irrespective of household (**Figure 1B**).

115 Hierarchical clustering analysis on reported symptoms demonstrated that five major symptom clusters were observed across the cohort (Figure 1C), including no symptoms, and symptoms 116 117 known to track with severe disease such as difficulty breathing, shortness of breath, and loss of 118 taste/smell. To identify those demographic parameters associated with infection status, principal 119 component analyses (PCA) were performed, where components were ordered according to their 120 proportion of explained variability in the data. PCA identified two components that explained at 121 least 10% of the variability in the data (Figure 1D). Infected and uninfected individuals were 122 distinguished in Component 1 by positive PCR tests and variables related to reporting symptoms 123 for SARS-CoV-2 infection. Select demographic variables further characterized individuals across 124 Component 2, including subject age, chronic conditions (e.g., hypertension, high cholesterol), and 125 BMI, but not sex, race, or household. These analyses demonstrate that medical co-morbidities 126 observed in hospitalized COVID-19 patients were also relevant in this non-hospitalized cohort.

127 Polyfunctional humoral immunity is induced following SARS-CoV-2 infection.

Given the central role of antibodies in SARS-CoV-2 immunity, we quantitatively and qualitatively profiled SARS-CoV-2 specific humoral immunity in the cohort. Using multiplexed Luminex

130 analyses, we measured plasma levels of different IgG subclasses (IgG1, IgG2, IgG3, IgG4), IgA

131 (IgA1, IgA2), and IgM-specific for SARS-CoV-2 antigens (full-length spike protein, the receptor-

binding domain (RBD), and the nucleoprotein [N]) and seasonal coronaviruses (OC43, HKU1,
229E, and NL63) spike proteins.

134 As expected, SARS-CoV-2 specific antibodies were significantly elevated in subjects with SARS-135 CoV-2 infection compared with uninfected individuals (Figure 2A, Figure S1). No significant 136 differences were observed between infection groups with respect to the levels of antibodies 137 against the seasonal coronaviruses. Sampling times post-infection differed across the cohort. 138 While the time between sampling and infection did not correlate with increasing/decreasing IgG1 139 across individuals, elevated levels of IgG4 were observed in samples collected further from 140 infection, suggesting temporal development of virus-specific IgG4 (Figure 2B). A subset of 141 subjects (n=18) returned for follow-up visits six months after visit 1 (and before any vaccination). 142 In these subjects, spike- and N-specific IgG responses were relatively stable over time (Figure 143 S2). However, a small but significant increase in spike-specific IgA1 was observed in the follow-144 up visit (Figure S2).

145 As both neutralizing antibodies and induction of antibody-mediated innate immune effector 146 functions have been associated with antibody-mediated protection against SARS-CoV-2 infection 147 [10, 20, 21], the ability of each subject's plasma to neutralize SARS-CoV-2 D614G pseudoviruses 148 and induce innate immune effector functions against spike-coated targets (phagocytosis by 149 monocytes (ADCP) or neutrophils (ADNP), complement deposition (ADCD), and NK cell 150 activation (ADNKA) was determined. Plasma from most infected individuals was found to possess 151 neutralizing activity and not be related to time from infection, yet interestingly a sizable subset of 152 people (n=20; 29.8% of infected individuals) did not make neutralizing antibodies (Figure 2C). 153 Similar results were observed for induction of innate immune effector functions (Figure 2D), 154 although the profiles among individuals varied (Figure S3A). To determine if specific antibody 155 subclasses or isotypes were associated with antiviral effector functions, we performed a 156 correlation analysis between SARS-CoV-2 specific antibody levels and effector functions. Among 157 infected individuals, spike and RBD-specific IgG1 were highly correlated with antiviral functional 158 activity and symptom score (Figure 2E, Figure S1B), suggesting that IgG1 predominantly drives 159 these antiviral functions, although it should be noted that IgG3 strongly correlated to ADCD. N-160 specific IgM was negatively associated with many of these effector functions including ADNKA, 161 ADNP, ADCP, and neutralization. While IgM is often observed early in infections (prior to IgG response), IgM levels were detected that were not significantly associated with days post-infection 162 163 or inversely related to virus-specific IgG. Thus, the IgM response we detected does not seem to 164 have a temporal relationship with antibody maturation and class-switching. Network analyses of all antibody responses against SARS-CoV-2 and the seasonal coronaviruses further confirmed 165 166 the association of SARS-CoV-2 spike and RBD-specific IgG1 with qualitative antibody functions 167 but with limited associations to other isotypes and specificities (Figure 2F). Together, these data 168 highlight the diversity of qualitative humoral immune responses observed among infected 169 individuals.

170 CD4+ and CD8+ T-cell immunity are induced following infection, and CD4+ Th1 responses 171 strongly correlated with SARS-CoV-2 serum IgG and neutralization.

To determine cellular immunity post-infection, we evaluated stored PBMCs from all subjects for CD4+ and CD8+ T-cell reactivity and cytokine secretion in response to SARS-CoV-2 spike

174 protein, nucleoprotein, or matrix peptide pools after in vitro stimulation for 24h. Activation was 175 assessed by flow cytometry of stimulated versus non-stimulated PBMC cultures by gating for 176 CD134-high expression on CD4+ T cells or CD69 expression on CD8+ T-cells as a modified 177 activation-induced marker expression (AIM) (Figure S4A,B). As previously reported in SARS-178 CoV-2 infected subjects [4, 24, 26], significant CD4+ and CD8+ T cell AIM to spike protein or 179 peptide were observed compared to non-infected subjects (Figure 3A). CD4+ T cell AIM 180 responses were stable over 6 months in the individuals who returned for a follow-up visit (Figure 181 **S2E-F)** and were not correlated with the day of sample collection (Figure S4F). Interestingly, a 182 subset of infected subjects had detectable T-cell responses with no observable antibody 183 responses (Figure S3A,B), indicating that these subjects exhibit cellular sensitization without 184 seroconversion [26].

185 To further characterize the types of T cell responses that are induced in infected individuals, we 186 measured cytokines indicative of specific T-helper (Th)-responses, cytotoxic T-cell responses, or 187 chemokines in stimulated PBMC culture supernatants compared with unstimulated PBMC. 188 Induced cytokine secretion was highly correlated among almost all restimulation antigens 189 including spike protein, spike peptide, N peptide, or matrix peptide (Figure S5). As anticipated [4, 190 24-28], Th1-biasing IL-2 and IFNy secretion was observed in response to spike and nucleoprotein, 191 but not matrix viral antigens, in infected subjects. Th1 cytokine secretion did not correlate with the 192 day of sample collection (Figure 3C-E, Figure S4F) but declined in follow-up visits of infected 193 subjects (Figure S2G-J). Although TNF α secretion alone was not associated with infection, a 2.5-194 or 4-fold change in the three Th1-associated cytokines (IL-2, IFNy, and TNF α) induced by spike 195 protein and nucleoprotein peptides was observed in infected subjects (Figure 3F, Figure S4E, 196 S4G). Restimulation with spike protein also induced Th2 and Th17 cytokines, including IL-5 and 197 IL-17, the latter of which was highly correlated to IL-2 responses (Figure S5). Significant changes 198 in parameters such as IL-4, IL-10, Granzyme B, and perforin were not observed for any stimulation 199 condition related to infection status (Figure S4E).

200 As T-cell and cytokine secretion can impact the generation of antibodies and have been 201 implicated in pre-existing immunity to seasonal coronaviruses, we correlated cellular immunity 202 measures with SARS-CoV-2 and seasonal coronavirus IgG antibodies (Figure 3G). CD4+ T-cell 203 AIM, IL-2 secretion, and Th1-associated cytokines were significantly correlated to plasma levels 204 of SARS-CoV-2 spike, RBD, and N IgG. Spike peptide pools but not protein for AIM significantly 205 correlated to OC43 and NL63 IgG. In contrast, symptom score was highly associated with TNFa, 206 IL-4, and IL-10, even though these cytokines individually were not different between infected and 207 non-infected subjects, suggesting that these cytokines track with disease severity.

208 Age drives immunity to SARS-CoV-2 infection.

The diversity of the study cohort (**Table 1**) allowed us to evaluate the relationship between age, sex, and SARS-CoV-2 immunity. In infected subjects, higher levels of chronic conditions and SARS-CoV-2 symptom scores were associated with increasing age (**Figure 4A**) and correlated with increased levels of spike-specific IgG1, neutralizing antibodies, IL-2, CD8+ T-cell activation, and the related antiviral cytokines perforin and Granzyme B (**Figure 4B-D**). Minimal changes in seasonal coronavirus IgG were observed with age (**Figure 4B**). Sex had no significant impact on

these measures (Figure 4B); however, both sex and age were significantly related to IgM
antibody levels to Spike and RBD (Figure 4B).

Immunity in infected subjects can be separated into two groups based on Th1 or Th2 biased immune responses and antibody isotypes (IgM/IgG1 or IgG2/IgG4).

219 To dissect the relationship between cellular and serologic immunity with all disease parameters 220 and demographic information, we used t-SNE and UMAP data visualizations for immune 221 response to SARS-CoV-2 proteins or peptides. These analyses resulted in two distinct populations (e.g., t-SNE 1 and t-SNE 2) verified by k-means clustering (Figure 5A, Figure S6A). 222 223 These populations were compared for all measures of SARS-CoV-2 immunity, demographic, 224 infection, or other seasonal coronavirus variables (Table S2). Across the demographic and 225 disease variables, older age was associated with population 1, and minor symptoms or specific 226 symptoms (nausea, loss of taste, runny nose, nasal congestion) were associated with population 227 2 (Figure 5B, Figure S6B,D). Sex, co-morbidities, infection status, or time from infection was not 228 associated with either population. With regard to immune measures, population 1 was defined by 229 typical SARS-CoV-2 immunity, including IL-2 secretion to spike, CD4+ AIM, antiviral antibody 230 functions (ADCP, ADNP), and elevated levels of IgM to SARS-CoV-2 spike or seasonal 231 coronaviruses (e.g., HKU1, Figure 5C). Neutralization was not directly associated with either 232 cluster but correlated strongly with Th1-responses and IL-2 in population 1 (Figure 5D, Figure 233 **S6E**). Alternatively, population 2 was characterized by non-classical immune measures indicative 234 of a Th2-biased response, including IL-4, IL-13 and IL-10 secretion to spike and peptide pools 235 and development of higher levels of IgG2 and IgG4 to RBD (Figure 5B, Table S2). Neutralization 236 in this population did not correlate to Th1 cytokines but was negatively correlated with IL-4 (Figure 237 **5D. Figure S6E**). In addition, perform and ADNK activities were higher, suggesting population 2 238 may have higher NK or NKT cell activity. These data indicate that within this non-hospitalized 239 cohort, SARS-CoV-2 immunity can diverge into Th1-biased immunity (observed in population 1) 240 or Th2-biased immunity (observed in population 2), likely related to patient age. It is possible that 241 lingering viral infection or antigen also contribute to population differences, as this showed up in 242 both UMAP and correlation analyses. (Figure 5E, Figure S6B).

243 These observations were complemented with a network analysis of immune parameters in SARS-244 CoV-2 infected subjects, which demonstrated that neutralizing and functional antibody levels were 245 associated with CD4+ T cell help (indicated by CD4+ AIM and induction of Th1 cytokines), 246 whereas T cell production of IL-4 and IL-10 were negatively associated with antiviral antibody 247 functions (Figure 5E). The univariate correlation analysis between these T cell parameters, 248 neutralization, and antibody effector functions in SARS-CoV-2 infected subjects further highlights 249 that specific CD4+ T cell responses track with development of qualitatively different antibody 250 responses (Figure S6F). Prior exposure to seasonal coronaviruses may also play a role in the 251 development of qualitatively different antibodies as IgM responses against the seasonal 252 coronaviruses, particularly 229E, were negatively associated with IL-4 and IL-10 (Figure 5E), 253 reflective of our t-SNE analyses (Figure 5C).

Together, these data suggest that the balance of Th1/Th2 CD4+ T-cell responses played a key role in developing qualitative SARS-CoV-2 antibody responses and points to a potential role for IgM, but not IgG1, responses against seasonal coronaviruses in promoting Th1 immunity.

257 **Post-vaccination responses are predicted by Th1 immunity.**

With ongoing vaccinations, it is also unclear how prior infection will shape long-term and vaccinemediated immunity. Vaccine responses and efficacy have been tied to the development of neutralizing antibody responses [11], although there is also strong evidence for T-cell or Th1 responses post-vaccination [8][35].

262 To understand how prior SARS-CoV-2 immunity resulting from infection impacted vaccine-263 mediated immunity, we obtained follow-up samples from a subset of infected subjects who received SARS-CoV-2 vaccine (n=32; age 16-79 years old (mean 43) and 63% female). These 264 265 subjects received either the two-dose mRNA vaccines from Pfizer (n=21) or Moderna (n=11) or 266 the single-dose J&J adenovirus vector vaccine (n=1). Blood collections spanned 2–315 days post-267 primary immunization, with 12 subjects having two or more samples collected (Figure 6A). As neutralizing antibodies have been linked to vaccine efficacy [20, 21], we determined post-268 269 vaccination neutralizing antibody titers. Comparison of neutralizing antibody levels pre- and post-270 vaccination demonstrated that vaccination significantly increased levels of neutralizing antibodies 271 (Figure 6B). Waning immunity was evident over time post-vaccination, particularly 6 months 272 following the second mRNA immunization (Figure 6B-C), as others have reported [21, 36, 37].

273

274 To determine if post-infection immune responses could predict neutralizing antibody responses 275 to vaccination and help validate the importance of the t-SNE and network analyses in **Figure 5**, 276 we performed a LASSO-selected regression analysis on neutralizing antibody responses 277 observed across all subjects and time post-vaccination, or <90 days or > 90 days post-vaccination 278 to identify the minimal features needed to predict neutralizing antibody responses within a given 279 time frame. LASSO-selected features were then used in a partial least squares analysis to identify 280 the variable importance in projection (VIP) features that predicted neutralization titers. Features 281 with VIP scores >0.8 were then used to generate a PCA to determine those features that 282 influenced vaccine-induced neutralizing antibody titer levels (Figure 6D-E).

283 Across all samples where collection time points spanned 2 to 315 days post-vaccination, one of 284 the main driving factors that predicted higher levels of neutralizing antibodies was the number of 285 days post-vaccination the samples were collected (Figure 6D), with samples collected before 90 286 days of vaccination having higher neutralizing antibodies than those collected afterwards. Post-287 infection immune parameters that predicted higher levels of neutralizing antibodies were CD4+ T 288 cell production of IL-2, IL-17A, as well as the levels of IgG1 specific for RBD and neutralizing 289 antibody titers post-infection (Figure 6D), suggesting that robust immune activation following 290 infection translated to elevated immunity following vaccination. Curiously, CD8+ activation 291 responses were negative predictors of post-vaccination neutralization responses (Figure 6D-E, 292 Figure S7). The importance of pre-existing immunity to seasonal coronaviruses was also verified 293 in this cohort as IgG1 OC43, IgM 229E, and IgG3 HKU1 were negative predictors of post-294 vaccination responses. Similar responses were observed within the samples collected within 3 295 months of vaccination and by correlation analyses (Figure S7A-B).

For samples collected after 3 months, older age, type of vaccine received, B-cell activating factor (BAFF), and lower levels of antibodies against the seasonal coronaviruses, including IgG1 OC43, IgM 229E, and IgA1 229E tracked with higher neutralizing antibodies (**Figure 6E, Figure S7B**),

suggesting that durable vaccine-mediated immunity is also shaped by prior SARS-CoV-2 andseasonal coronavirus immunity and age.

Finally, a comparison of the post-vaccination neutralizing antibody titers between subjects in population 1 (Th1 biased immunity) and population 2 (Th2 biased immunity) showed a trend towards higher neutralizing antibodies in population one post-vaccination (**Figure 6F**). This finding indicates that the two observed clusters partially explain diversity in SARS-CoV-2 antigen responses post-infection or vaccination based on CD4+ T-cell responses, age, and non-IgG1 antibody isotypes to SARS-CoV-2 or seasonal coronaviruses.

307

308 DISCUSSION

309 This is among the first studies to comprehensively measure serological and cellular measures, 310 combining a systems serology approach with T-cell and cytokine analysis. Our key findings 311 confirmed that CD4+ Th1 responses and age track with qualitative features of humoral immunity. 312 and we demonstrated that post-infection responses shape levels of vaccine-induced neutralizing 313 antibody titers. Importantly, this study was performed in a non-hospitalized community cohort, 314 encompassing individuals across a range of ages who experienced typical asymptomatic or mild-315 moderate disease, reflective of the vast majority of SARS-CoV-2 infections. As previously 316 reported[10], infected subjects developed anti-spike, RBD, and nucleoprotein antibodies that 317 exhibit polyfunctionality with multiple antiviral effector functions (Figure 2, Figure S3). 318 Accordingly, CD4+ and CD8+ T-cell responses to spike and peptide pools were also significantly 319 altered between infected and non-infected subjects, including high levels of Th1 cytokine 320 expression characterized by high levels of IL-2 and also INFy (Figure 3) as expected from 321 previous studies [4, 24-28, 38].

322 We observed diversity in immune responses following infection in this cohort, including infected 323 subjects that did not develop neutralizing antibody responses (Figure 2) and T-cell responses in 324 the absence of seroconversion (Figure S3). Age but not sex correlated to many of our immune 325 measures, BMI and to the symptom severity experienced by infected subjects (Figure 4). This 326 would confirm that age is a primary driver of immunity, with reduced IgG and neutralizing 327 antibodies observed in younger ages as expected from previous reports [39, 40]. However, other 328 antibody functions, including complement and NK activation were unaffected. Curiously IgM and 329 IgA levels did not correlate with post-infection duration and were not reduced over a second study 330 visit (Figure 2, Figure S2), though older ages were associated with higher levels of IgM (Figure 331 4). IgM is traditionally an early response to infection, but sustained expression has been reported in asymptomatic or symptomatic convalescent patients [17, 41]; though others have found 332 333 persistent IgM levels associated with reinfection or prolonged shedding of virus [42] or observed 334 decreases immediately following infection [38]. We were unable to assess early IgM responses 335 following infection, as the average study visit for this cohort was 93 days post-infection (Table1). 336 Taken together the results presented here suggest that age-related responses to SARS-CoV-337 infection are likely related to isotypes generated during infection, altering antibody effector functions. Since IgM-expressing B-cells play important roles in humoral immunity for early and 338 339 late antibody responses, and antigen presentation are associated with complement deposition

[43, 44], it is possible that IgM levels in our cohort could be more than a temporal antibodymaturation response and should be studied further.

342 The combined induction of functional cellular and humoral immunity is likely a key factor in long-343 term immunity. We observed a much higher correlation of antibody measures to CD4+ T-cells 344 and cytokines than to CD8+ T-cells (Figure 3, 5), consistent with other reports on humoral 345 memory [45, 46]. However, CD8+ T cell activation was also significantly detected and altered by 346 age (Figure 3, Figure 4), and CD8 activation to spike peptide pools seemed to limit post-347 vaccination neutralization responses (Figure 6). This finding may reflect that specific CD8+ T-cell 348 populations limit longevity of neutralization titers after infection, as others have suggested [47] or 349 reflect a robust CD8+ T-cell response that is also protective [48]. Interestingly, combined analyses 350 showed that infected subjects could be delineated into two groups based on a Th1- versus Th2-351 biased immunity that further tracked with differential development of neutralizing antibodies 352 following vaccination. Importantly, individuals who developed a more Th1-biased immune 353 response following infection, including production of Th1 cytokines from activated T-cells and 354 development of antiviral antibodies capable of inducing both neutralization and innate immune 355 effector function, had elevated levels of neutralizing antibodies post-vaccination (Figures 5-6). 356 Antibody-dependent, complement-mediated delivery of antigen to dendritic cells has been shown 357 to enhance production of neutralizing antibodies [43], thus in addition to having higher numbers 358 of memory B cells, one potential hypothesis is that enhanced delivery of vaccine antigens to 359 antigen presenting cells by existing SARS-CoV-2 specific antibodies helps drive higher 360 neutralizing antibody levels.

361 The development of Th1-biased responses in subjects within cluster 1 tracked with overall older 362 age, but not with symptom severity or SARS-CoV-2 infection. Intriguingly, subjects in cluster 2 363 reported experiencing more minor symptoms (e.g., nausea, runny nose (coryza), nasal 364 congestion, cough, and headache) or specific symptoms (e.g., loss of taste) and had elevated 365 levels of virus-specific IgG2 and IgG4 compared with subjects in cluster 1. While virus-specific 366 IgG1 and IgG3 were not different between the two clusters, antibody functionality and 367 neutralization were significantly different, highlighting that antibody features beyond IgG subclasses may further drive differences in antiviral functionality between the two groups. 368 369 Antibody glycosylation can further modify the induction of innate immune effector functions. While 370 we did not evaluate antibody glycosylation in this study, several studies have found that severe 371 SARS-CoV-2 infection in hospitalized or critically ill subjects is associated with increased antibody 372 afucosylation, leading to increased inflammation and innate immune cell-mediated 373 immunopathology [49-52].

374 This study also revealed an association with Th2 cytokines, including IL-4, IL-13, and IL-10, which 375 inversely correlated to neutralization after infection but only weakly to post-vaccination 376 neutralization (Figure 2, Figure 6, Figure S7B). A Th2 profile has also been implicated in severe 377 COVID disease [31], though these patients were not in our study population. IL-10 was strongly 378 correlated with IgA response to spike in our cohort, which was a key factor in lower post-379 vaccination neutralization titers and longevity >3 months (Figure 6, Figure S7). A similar IL-4/IL-380 13 cytokine profile by T-cells was associated with the development of memory IgA+ B cells and 381 not neutralization in cases of mild or severe COVID-19 [45]. However, others have shown that 382 IgA is dominant as an early neutralizing antibody response to SARS-CoV-2 infection in mucosal

tissue and blood and correlates to IgG [53, 54]. mRNA vaccination is known for boosting high levels of neutralizing serum antibodies but not mucosal IgA responses even in previously infected individuals [55]. However, these findings suggest that IgA responses play a negative role in postvaccination neutralizing antibody magnitude and duration and may be the result of IL-10 secretion that that should be explored further. Taken together, this data indicate a key role for cellular immunity and cytokine biases in infection outcomes and post-vaccination responses.

389 Whether prior exposure to seasonal coronaviruses shapes SARS-CoV-2 specific immunity has 390 been a key question since the beginning of the pandemic. Pre-pandemic pediatric samples have 391 been a higher level of cross-reactive IgM to SARS-CoV-2, compared with adults who have higher 392 levels of IgG and IgA, presumably from these seasonal coronaviruses [56]. These pre-existing 393 antibodies, particularly to OC43, are increased following infection but not vaccination [57-59], 394 OC43 antibodies have been linked to antibody development post-infection and COVID-19 survival 395 in hospitalized patients [58] and are boosted following infection but not vaccination [57]. While no 396 differences were observed in this cohort with respect to levels of antibody isotypes to seasonal 397 coronaviruses by infection status (Figure 2, Figure S1), there were significant correlations 398 between antibodies to SARS-CoV-2 spike, and nucleoprotein and those to spike proteins of 399 seasonal coronaviruses (Figure 2F). Age did not correlate with the magnitude of these seasonal 400 coronavirus IgG antibodies (Figure 4). We also observed that OC43 and NL63 IgG levels 401 correlated with activation of T cells with spike peptide pools, but not protein (Figure 3), indicating 402 this peptide pool contained epitopes known to overlap with seasonal coronaviruses as previously 403 reported [60] that was not observed with full protein.

404 Variable reduction analyses identified population clusters that differed significantly in their 405 antibody isotypes to seasonal coronaviruses (IgG1, IgM, IgA in population 1 vs IgG2, IgG4 in 406 population 2, Figure 5, Figure S6, Table S2), suggesting that these antibody responses, 407 particularly IgM 229E and IgG1 OC43, may impact the development of SARS-CoV-2 immunity. 408 IgM responses to 229E spike protein were negatively correlated with Th2 cytokines IL-4 and IL-409 10 post-infection (Figure 5E) and post-vaccination neutralization responses (Figure 6D-E, 410 Figure S7A-B). IgG1 levels to OC43 spike protein negatively impacted neutralization responses 411 within <3 months post-vaccination (Figure 6D, Figure S7A-B), but positively affected longevity 412 of post-vaccination responses (Figure 6E, Figure 7B). Thus, we confirmed evidence that pre-413 existing to seasonal coronaviruses immunity shapes infection and vaccination responses to 414 SARS-CoV-infection [57-59]. However, this effect differed by time post-vaccination and supported 415 an important role for non-IgG1 isotypes (IgM, IgG3) to seasonal coronaviruses that warrants 416 further study.

417 Study limitations primarily involved using SARS-CoV-2 infection to differentiate subjects rather 418 than pre-pandemic samples. In addition, the assays were limited to peripheral blood samples and 419 not tissue-specific responses, which included only effector functions to spike protein and cytokine 420 secretion instead of T-cell subset analyses. Detection of secreted cytokines allowed a greater 421 number of cytokines to be evaluated but prevented confirmation of cells producing cytokines as 422 would be observed intracellular stained cytokines for specific T-cell populations. However, 423 cytokines between spike or peptide pools were highly correlated (Figure S5), indicating T-cell 424 production. Also, high expression of IL-2 has been routinely observed from CD4+ T-cell and not 425 CD8+ T-cells after SARS-CoV-2 infection [28, 38]. In this study, IL-17A secretion was closely

426 correlated to IL-2 and Th1 cytokine release after stimulation with protein or peptide pools, 427 suggesting that IL-17A may be serving as a proxy for a Th1/Th17 subset, as identified in other 428 post-vaccination studies [61] which should be more closely examined. Finally, while the critical 429 role for age in SARS-CoV-2 immunity was validated, it remains an ongoing question of why 430 children exhibit less severity with infection and how differences in qualitative features of immunity 431 depend on patient age.

432 Our study used samples collected from subjects only shortly after the pandemic which will be 433 difficult to perform as COVID subsides and vaccination rates increase in the general population. 434 Our findings indicate that SARS-CoV-2 specific humoral responses and functions are likely 435 shaped by age, disease severity, quality of CD4+ T cell help, IgM or other non-IgG1 antibody 436 isotypes to seasonal coronaviruses. SARS-CoV-2 specific T-cell responses, particularly IL-2 437 secretion, can be their own correlate of protection. Further studies combining powerful systems 438 serology tools with T-cell function measures with other cohorts, tissue types, and timeframes will 439 continue to tease out how these factors contribute to the diversity in SARS-CoV-2 infection 440 outcomes and duration of immunity, including risks of breakthrough infections.

441

442 Acknowledgements

We sincerely thank the CSI study participants. Funding for this study was provided under NIH Project U54CA260581-01. Funding for CVM and SSD was supported by the Telomere Research Network, NIH Project 5U24AG066528 (SSD). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

447 Author Contributions

- 448 449 Conceptualization, E.B.N., B.M.G., J.E.R., J.S.S., M.L.D., S.S.D., K.J.Z; Methodology, E.B.N., B.M.G., J.E.R; Investigation, A.E.M., E.E., I.V.T., T.J.Y., S.B., S.C., D.H.E., A.R.S., S.N.H., 450 451 K.E.O., S.J.B., B.N. T.H.; Resources, M.L.D., C.Y.Z., I.V.T., C.V.M., S.E.C., A.A., A.E.S., M.J.G., 452 N.D.F., E.J.E., A.D.P., S.J.L., J.K.K.; Data Curation, E.B.N., A.E.M., E.E., J.G.S.; Visualization, 453 E.B.N., B.M.G., J.G.S.; Writing – Original Draft, E.B.N., B.M.G., A.E.M, EE, J.G.S.; Writing – 454 Review & Editing, J.E.R., J.S.S., K.J.Z., J.G.S., J.K.K.; Funding Acquisition, E.B.N., B.M.G., 455 J.E.R, J.S.S. 456
- 457 **Declaration of Interests.** The authors declare no competing interests.
- 458
- 459 **TABLE AND FIGURE LEGENDS**
- 460
- 461 **Table 1. Composition of study cohort by SARS-CoV-2 infection status.**
- 462
- Table S1. Study questionnaire on demographic and COVID-19 factors.
- 464

Figure 1. Cohort composition includes a range of asymptomatic or mild to moderate
 disease subjects. (A) Days post-symptom onset or possible viral exposure for last SARS-CoV 2 PCR positive test for each subject and indicated day of first study visit. The bars represent the

468 median number of days. (B) Symptom score as a composite of major and minor COVID-19 469 symptoms, range 0-21. Red circles indicate infected subjects and white circles indicate 470 uninfected subjects. (C) Hierarchical clustering of individual subjects by symptoms with 471 associated heatmap for reported symptom or infection and demographic information listed 472 underneath (blue colors or color ranges indicate positive, high, female, or older age categories). 473 Major symptoms are shown colored red. (D) PCA analysis of subject's infection and demographic 474 data colored by SARS-CoV-2 infection status with eigenvalues and eigenvector variables shown 475 for components 1 and 2.

476

477 Figure 2. Antibody isotypes dictate effector functions post-infection. (A) IgG1 responses to 478 spike, RBD or N SARS-CoV-2 specific antigens and spike-specific responses to seasonal 479 coronaviruses OC43, HKU1, 229E, NL63 for each subject by SARS-CoV-2 infection status. (B) 480 IgG1 or IgG4 spike-specific expression by days post-infection or possible exposure with significant Spearman's correlations indicated. (C) Neutralization responses by SARS-CoV-2 481 482 infection status. (D) ADNKA, ADCD, ADNP, or ADCP responses by SARS-CoV-2 infection status. 483 (E) Correlation matrix for indicated measures with heatmaps of Spearman's rho values (left) and 484 p values (right). (F) Network of indicated antibody responses with the color of connecting lines 485 representing Spearman's rho values. Bars represent mean +/- SD. Significance by Mann Whitney 486 indicated as p<0.05 (*), <0.01 (**), or <0.001 (***). Area under the curve (AUC).

487

Figure S1. Expanded humoral analysis of the study population. (A) Strong concordance of
results between spike and nucleoprotein IgG by Luminex-based analysis and ELISA optical
density results. (B) Symptom score versus IgG1 responses to spike with Spearman's correlation
indicated. (C) IgG2, IgG3, IgG4, IgA1, IgA2, IgM responses to spike, RBD or N SARS-CoV-2
specific antigens, and spike-specific responses to seasonal coronaviruses OC43, HKU1, 229E,
NL63 for each subject by SARS-CoV-2 infection status.

- 494
- 495 Figure S2. Stability of cellular and humoral measures between multiple study visits. (A) 496 Schematic of original and return study visit by date for selected SARS-CoV-2 infected subjects 497 (n=18). Immune measures were compared between first and second subject visits (indicated by line) and the difference calculated for each subject with bar at the mean +/- SD; including: (B) 498 499 spike IgG1, (C) spike IgA1, (D) neutralization responses, (E) CD4 T cell AIM to spike, (F) CD4 T 500 cell AIM to spike peptide, (G) IL-2 secretion to spike, (H) IL-2 secretion to spike peptide (fold 501 change from unstimulated), (I) IFNy secretion to spike, (J) IFNy secretion to spike peptide. 502 Significance by Wilcoxon signed rank test indicated as p<0.05(*), <0.01 (**), or <0.001 (***).
- 503

Figure S3. Individual subject responses. (A) Pie charts of each subject by antibody functions
 and select cellular measures. Black boxes indicate subjects with evidence for cellular immunity
 without seroconversion. (B) CD4+ T cell AIM, CD8+ T cell AIM, IL-2 secretion, or IFNγ secretion
 to spike protein by spike or nucleoprotein IgG serostatus.

508

509 **Figure 3. CD4 Th1 responses to spike, nucleoprotein, and matrix antigens strongly** 510 **correlate with SARS-CoV-2 serum IgG and neutralization responses.** (A) Spike-specific AIM 511 changes in CD4 or CD8 T cells by SARS-CoV-2 infection status (% of CD4 or CD8). CD8 T cell

512 AIM excludes three high responders in the SARS-CoV-2 infection group (values of 8.6, 14.7, and 513 15.6). (B) T cell AIM results by day post-infection or possible exposure with significant Pearson's 514 correlations indicated. (C) Pie charts of log-transformed mean cytokine levels to spike protein or 515 peptide pools (spike, nucleoprotein or matrix) expressed as fold change from unstimulated with 516 color key indicated. (D) Spike-specific IL-2 and IFNy cytokines secretion expressed as fold 517 change from unstimulated by infection status. (E) Cytokine changes by day post-infection or 518 possible exposure with significant Pearson's correlations indicated. (F) Number of IL-2, IFNy, or 519 TNFα cytokines expressed at fold change >2.5 from unstimulated cells by SARS-CoV-2 infection 520 status. (G) Correlation matrix for indicated measures with heatmaps of indicated Spearmans' rho 521 (left) and p values (right). Bars shown at mean +/- SD. Significance by Mann Whitney indicated 522 as p<0.05 (*), <0.01 (**), or <0.001 (***).

523

524 Figure S4. Measures of cellular immunity in study population. (A) Example AIM analysis by gating CD134-high expression on CD4 T-cells (CD4+, CD8-, CD3+ DUMP- (dead/CD33) or CD69 525 526 expression on CD8 T-cells (CD4-,CD8+,CD3+,DUMP-). (B) CD4 T cell AIM responses for mock 527 and stimulated conditions for each subject (line) by infection status. (C) CD4 or CD8 T cells AIM 528 to spike peptide pools by infection status. (D) CD8 T cell AIM responses for mock and stimulated 529 conditions for each subject (line) by infection status. (E) Spike specific cytokine secretion 530 expressed as a fold change from unstimulated cells by infection status. (F) Number of IL-2, IFNy, 531 or TNF α cytokines expressed at fold change >2.5 from unstimulated cells by day post infection or possible exposure. (G) Number of IL-2, IFNy, or TNFa cytokines expressed with antigen 532 533 stimulation at fold change >4 from unstimulated cells by infection status. Bars at mean +/- SD. 534 Significance by Mann Whitney test indicated as P<0.05 (*), <0.01 (**), or <0.001 (***).

535

Figure S5. Strong correlation between stimulation antigens used for T-cell AIM and cytokine secretion assays. Correlation matrix for indicated measures after stimulation with spike protein or spike, nucleoprotein, or matrix peptide pools stimulation displayed as heatmaps of indicated Spearman's p values (A) and rho correlation coefficient (B).

540

541 Figure 4. Age is a significant driver of disease severity and development of SARS-CoV-2 542 immunity. (A) Age of each subject, percent of individuals with chronic conditions, symptom score 543 of each subject and percent of individuals that meet COVID-19 case definition by age category. 544 (B) Correlation matrix for age, age category and sex (male = 1, female = 2) with heat maps of 545 indicated Spearmans' P or rho values. (C) Spike-specific responses for IgG1 and IgGA1, ADNP, 546 and neutralization responses of each subject by age category. (D) CD8 AIM changes for spike 547 protein or peptide pool and Granzyme B and IL-10 fold change for spike protein by age category. 548 Significance by ANOVA with Dunn's post-test or logistic regression model with pairwise contrast 549 indicated as P<0.05 (*), <0.01 (**), or <0.001 (***).

550

Figure 5. SARS-CoV-2 immunity can be clustered into two populations based on age, Th1/Th2 responses, antibody isotypes, and effector functions. (A) An imputed dataset for all SARS-Co-V immunologic variables was used for t-SNE analysis and then K-means clustering for comparison of variables. No seasonal coronavirus data, infection history or demographic data was used. All imputed data were required to have at least 60% of non-missing cell values. (B)

556 Graphs of demographic and SARS-CoV-2 infection variables defined by cluster. (C) Graphs of 557 SARS-CoV-2 or seasonal coronavirus immunity variables defined by cluster. Significant Kruskal-558 Wallis test between tSNE clusters indicated by P<0.05 (*), <0.01 (**), or <0.001 (***). (D) Dot plots 559 by indicated measures for subjects included in cluster 1 (pink) or 2 (blue) with spline trend line 560 (black) shown in log scale. (E) Correlation network across immune and disease features that were 561 significantly associated across SARS-CoV-2 infected individuals.

562

563 **Table S2. Kruskal-Wallis analyses comparing t-SNE Cluster 1 and 2 populations and** 564 **demographic, infection, or immunologic variables.**

565

566 Figure S6. Supporting data for population clusters by SARS-CoV-2 immunity. (A) Imputed 567 dataset for all SARS-Co-V immunologic variables was used for UMAP analysis. The blue and 568 red shaded regions represent clusters of UMAP values determined by the K-means clustering 569 approach. All imputed data were required to have at least 60% of non-missing cell 570 values. (B) Graphs of demographic and SARS-CoV-2 infection variables with correlation 571 significance to UMAP 1 or 2 indicated P<0.05 (*). (C) Graphs of variables (P<0.05) significantly 572 correlated with UMAP 1 or 2 at P<0.05. (D) Additional tSNE analysis graphs color-coded with 573 indicated variables for SARS-CoV-2 infected subjects only. (E) Correlation matrix for indicated 574 measures with heatmaps of Spearman's rho values and p values by cluster 1 (right) or cluster 2 575 (left). (F) Validation of key tSNE findings using unimputed dataset from SARS-CoV-2 infected 576 subjects with spline trend line (blue or orange) shown all graphs in log scale except Th1 cytokines 577 to Spike (number of >2.5 fold change for IL-2, IFN, TNF).

578

579 Figure 6. Post-vaccination responses are predicted by SARS-CoV-2 immunity post-580 infection. (A) Sample timeline for select subjects with SARS-CoV-2 infection who were followed 581 for post-vaccination (PV) sample collections (n=32). (B) Neutralization antibodies in these 582 subjects pre- or post-initiation of vaccination colored by vaccine type. Spline trend line (black) 583 shown for post-vaccination samples with Spearman's correlation indicated (for samples collected 584 post-17 days). (C) Titers of neutralizing antibodies are plotted according to days from the 585 completion of the primary vaccine series. (D-E) Predictive modeling with feature reduction analysis was used to determine the post-infection immune features that predicted neutralizing 586 587 antibody titers across all post-vaccination time points (D) or >3 months (E). The selected features 588 that best predicted post-vaccine neutralizing antibody titers in a partial least squares regression 589 analysis are shown in (i), and features with a VIP score >0.8 were used in a principal component 590 analysis (ii). (F) Post-vaccination neutralizing antibody titers in samples from subjects from cluster 591 1 or cluster 2. Mann-Whitney analysis was used to determine statistical significance as indicated 592 or P <0.001 (***).

593

Figure S7. Expanded analysis of post-infection immune features that predict or correlate with neutralizing antibody titers after vaccination. (A) Predictive modeling with feature reduction analysis was used to determine if specific post-infection immune features predicted post-vaccine neutralizing antibody titers <3 months. The selected features that best predicted post-vaccine neutralizing antibody titers in a partial least squares regression analysis are shown in (i), and features with a VIP score >0.8 were used in a principal component analysis (ii). (B)

600 Correlation matrix for post-infection/pre-infection immune measures to post-vaccination

601 neutralization responses with heatmaps of indicated Spearman's rho and p values for all samples

or >90 days samples from completion of vaccination series. (C) Graphs of select measures from

- 603 post-infection/pre-infection immune measures to post-vaccination neutralization responses for all
- samples or >90 days samples from completion of vaccination series.
- 605

606 Methods

607

608 Study design and subject recruitment

The study was a rolling prospective cohort of subjects recruited from communities in New Orleans between June 2020 to February 2021. Subjects or households with suspected or confirmed SARS-CoV-2 infection were recruited from the Greater New Orleans community under Tulane Biomedical Institutional Review Board (federalwide assurance number FWA00002055, under study number 2020-585). Enrolled subjects completed a study questionnaire regarding infection and demographic information and provided a blood sample. A subsample of subjects returned for

- 615 a follow-up visit.
- 616

617 SARS-CoV-2 infection and COVID-19 case classification

618 History of SARS-CoV-2 infection was defined as 1) clear evidence of immunity (SARS-CoV-2 S 619 or N-specific IgG), or 2) detection of plasma viral RNA as described below, or 3) fulfillment of the 620 Centers for Disease Control and Prevention (CDC) case definition of confirmed or probable 621 COVID-19 infection (an individual with a) confirmatory or presumptive laboratory criteria including history of positive SARS-CoV-2 PCR or antigen test or b] absence of negative PCR/antigen test 622 623 that was performed 2 days prior to 5 days after onset of symptoms and clinical criteria with certain 624 symptoms and fulfill the epidemiological criteria with exposure to a family or household contact 625 with known SARS-CoV-2 [62]).

626

627 Symptoms and illness severity scores

A general symptom score was calculated according to the September 2021 CDC classification (prior to circulation of the Omicron variant). Two points were given according to each major symptom: cough, shortness of breath, difficulty breathing, loss of smell, and loss of taste. Onehalf of a point was given for each minor symptom: fever, runny nose, nasal congestion, sore throat, diarrhea, vomiting, fatigue, muscle aches, chills, nausea, and headache. Total symptom score was calculated as the sum of the major and minor scores.

634

Because illness severity is not necessarily measurable by the point-based approach used for the general symptom score, it was calculated according to clinical manifestations thresholds based on lung involvement and impairments, as detailed in Baj et al. (2020, [63]). Specifically, the severity score was defined as severe (abdominal pain, shortness of breath, difficulty breathing, chest pain, vomiting, nausea, diarrhea); moderate (fever, cough, runny nose, fatigue, muscle aches, loss of smell, headache, sore throat, loss of taste, nasal congestion, chills, repeated chills, hair loss, toes); and asymptomatic (no reported symptoms). Hair loss was considered to be

typically associated with long-term COVID-19 symptoms and thus was not considered as anacute, severe symptom.

644

645 Continuous predictors

Age was based on self-reported birth date at study enrollment. Body mass index (BMI) was defined as weight in kilograms divided by height in meters squared. For adults, BMI was calculated as: as <18.5 (underweight), 18.5-30 (normal), and >30 (overweight/obese). For children (aged under 18 years), BMI was calculated as <5th percentile (underweight), between the 5th and 95th percentile (normal), and greater than the 95th percentile (overweight/obese).

651

652 Sample collections

Blood was collected from subjects and plasma and peripheral blood mononuclear cells (PBMCs)
and were isolated by density gradient centrifugation in Leukosep tubes (Greiner Bio One) and
Ficol-Paque PREMIUM 1.078g/ml (Cytiva) [64, 65]. Plasma was removed and stored at

656 -80°C or heat-inactivated at 56°C for 30mn before testing. PBMC were washed, counted, and

supported in FBS-10% DMSO at 1×10^7 cells/ml. Aliquots of cells were frozen at -80C in a

Nalgene Mr. Frosty container (Nalgene Labware, Rochester, NY) before final storage in liquid

- 659 nitrogen.
- 660

661 Plasma viral RNA detection

662 RNA viral load was measured with a sensitive SARS-CoV-2 specific CRISPR assay as previously 663 reported [33, 34]. Twice the limit of viral detection, or 2x10⁶ as RNA abundance expressed as the 664 relative photoluminescence intensity of the sample was used as definitive evidence of SARS-665 CoV-2 infection.

666

667 Determination of antigen-specific antibody reactivity by multiplexed Luminex analysis.

668 Recombinant SARS-CoV-2 antigens (full-length spike, RBD, and N) and the recombinant spike 669 protein from OC43, HKU1, 229E, and NL63 (Frederick National Laboratories) were coupled with 670 MagPlex beads (Luminex) via sulfo-NHS coupling chemistry. Heat-inactivated samples were 671 diluted at 1:50 in 1X PBS + 0.1% bovine serum albumin (BSA) + 0.05% Tween20 and incubated with antigen-coupled beads for 2 hours. Beads were washed and incubated with 0.65µg/ml of PE-672 673 labeled secondary antibodies specific for the human antibody subclasses IgG1 (Clone HP6001; 674 Southern Biotech), IgG2 (Clone HP6002; Southern Biotech), IgG3 (Clone HP6050; Southern 675 Biotech), IgG4 (Clone HP6025; Southern Biotech), IgA1 (Clone B3506B4; Southern Biotech) IgA2 676 (Clone A9604D2; Southern Biotech), IgM (Clone UHB, Southern Biotech) for 1 hour at room 677 temperature. Beads were washed three times with assay buffer and analyzed on a MagPix 678 instrument (Luminex, Austin, TX). The median fluorescent intensity for 50 beads/region was 679 recorded. SARS-CoV-2 seronegative plasma samples were used to establish baseline reactivity 680 and thresholds for positivity.

681

682 ELISA and Neutralization assays

Recombinant SARS-CoV-2 spike for use in ELISAs was produced in-house by stable expression
 of a modified phCMV based plasmid that encodes the pre-fusion trimeric SARS CoV-2 spike

685 protein with the D614G mutation (kindly provided by Dr. Kate Hastie (La Jolla Institute for

Immunology)[66, 67]). Stable expression was maintained via blasticidin selection in stably
 transfected 293F cells. Recombinant protein was purified from clarified culture medium by affinity
 chromatography on Streptactin X affinity columns. RBD (aa321-535) was similarly expressed in
 the phCMV plasmid and purified on Streptactin X affinity columns.

690

A DNA fragment encoding SARS CoV-2 N protein, including its natural leader sequence was generated by PCR of full-length N protein gene from a lentiviral N Protein expression vector (pLVX-EF1alpha-SARS-CoV-2-N-2xStrep-IRES-Puro, which was a gift from Nevan Krogan (Addgene plasmid # 141391 ; http://n2t.net/addgene:141391; RRID:Addgene_141391, [68]). This fragment was inserted in place of the RBD sequence in the above expression plasmid upstream of the double strep-tag sequence using NEB gene builder.

697

698 Wells of 96-well ELISA plates (Costar, Easy Wash) were coated for 1 hour at room temperature 699 with purified SARS CoV-2 spike protein (500 ng/ml in 100 mM sodium bicarbonate buffer). Wells 700 were washed X 5 and blocked for 1 hour at +37°C. Blocking and dilution buffers consisted of 701 0.5%Tween +5% dry milk+ 4%whey protein (BiPro, Le Sueur, MN) +10%FBS in 1xPBS. After 702 wells had been washed and blocked, 100 ul heat-inactivated sera or plasma samples diluted to 703 1:100 were incubated in antigen-coated and uncoated wells for 1 hour. Wash buffer consisted 704 of PBS with 500 mM NaCl and 0.2% Triton X. The higher salt content of the wash buffer greatly 705 reduced background noise. Bound IgG was detected with peroxidase-conjugated goat anti-IgG (Jackson ImmunoResearch) and diluted at 1:15.000. Color was developed with TMB-H202 and 706 707 stopped with 1 M phosphoric acid. Absorbance (optical density [OD]) was read at 450 nm. In 708 experiments where samples were tested in wells with and without spike protein, net ODs were 709 calculated by subtracting background OD readings from OD readings with spike protein. Cut-off 710 OD values were then calculated based on testing of >100 pre-COVID-19 samples. Net OD values 711 >0.5 were considered positive. The Spike protein ELISA for IgG antibodies has been validated by 712 testing a standard set of positive and negative samples provided by NCI SeroNet staff. These 713 validations showed sensitivity and specificity for the imunoassay as 98% and 100%, respectively). 714

Similar ELISAs were run with purified RBD and N protein-coated in wells. For the RBD ELISA,
protein was coated at 500 ng/ml in 100 ul of 100 mM sodium bicarbonate. For the N protein ELISA,
protein was coated at 2 ug/ml. Otherwise, the ELISA procedure was the same as for the spike
protein ELISA.

719

720 Neutralization of SARS CoV-2 in Pseudovirus Assay

721 CHO cells were generated and stably expressed ACE2 by transfecting CHO cells with an ACE2 722 expression plasmid containing the blasticidin resistance gene. ACE2 expressing cells were 723 selected in medium containing 10 ug/ml blasticidin ml. Blasticidin-resistant cells were expanded 724 and selected for high level ACE2 expression by flow cytometry of cells binding a FITC-labeled 725 murine Mab to ACE2 (Sino Biologicals Cat # 10108-MM37-F). ACE2 positive cells have been 726 sorted twice and have stably expressed ACE2 through multiple passages over 4-5 months with 727 gradual diminishment of luciferase signal induced by pseudovirus infection. Cell lines were 728 cryopreserved, and, as needed, cells were periodically thawed and freshly grown for continued

studies. CHO-ACE2 cells were similar in SARS CoV-2 susceptibility to the 293T/ACE2 cell line
 developed by Dr. Farzan [69] but have better adherence to tissue culture surfaces.

SARS-CoV-2 neutralizing antibodies were assessed in serum or plasma samples with sensitive,
high-throughput pseudovirus assays. Virus neutralization was measured in CHO/ACE2 cells. The
pseudovirus assay was originally developed by Drs. Barney Graham and others at Vaccine
Research Center at the National Institutes of Health (NIH). The assay was formally optimized and
validated in Dr. David Montefiori's laboratory at Duke University. The materials and protocol were

- kindly provided to the Robinson lab by Drs. Graham and Montefiori.
- For pseudovirus production, four expression plasmids were obtained from NIH Vaccine Research
 Center. These included an expression plasmid for full-length spike protein of the Wuhan-1 strain
 containing the D614G amino acid chain (VRC7480.G614) [70], a pCMV ΔR8.2 lentivirus
 backbone plasmid (VRC5602) [71], the VRC5601 plasmid pHR' CMV Luc containing the firefly
 luciferase reporter gene [71], and VRC9260 for TMPRSS2 expression. Pseudoviruses were
 produced by co-transfection of the four plasmids into 293T cells grown in T75 flasks with Fugene
 6 as transfection reagent. Virus stocks are collected 3 days after transfection, clarified, passed
- through a 0.45 μ m filter, and stored in aliquots at -80°C.

745 For neutralization, a predetermined optimal dose of pseudovirus was incubated with 8 serial 3-746 fold dilutions of heat-inactivated serum or plasma samples in 150 µl medium for 1 h at 37°C in 747 96-well tissue culture plates. CHO/ACE2 cells, suspended by the action of TrypLE enzyme, were 748 added to wells (10,000 cells in 100 µL medium per well). One set of eight control wells received 749 cells + virus (virus control), and another set of eight wells received cells only (background control). 750 After 66-72 hours of incubation, the medium was removed by gentle aspiration. Then, 100 ul of 751 1:6 dilution of Promega BriteGlo in Glo lysis buffer was added to the wells with mixing. Plates 752 were incubated for 7 minutes at room temperature, after which luminescence was measured in a 753 Biotek Synergy H1 Luminometer. Neutralization titers were defined as the serum dilution (ID50) 754 at which relative luminescence units (RLU) were reduced by 50% compared to virus control wells 755 after subtraction of background RLUs (determined by GraphPad Prism, version 9 for macOS, 756 GraphPad Software, San Diego, California USA).

- 757 Determination of Spike and Nucleoprotein IgG seropositivity
- 758 ELISA and Luminex results were compared for Spike or Nucleoprotein seropositivity for IgG or 759 IgG1, respectively. Any consistent results, disagreements or borderline positive/negative results
- 760 were coded as indeterminant.
- 761

762 Antibody-dependent NK cell degranulation and activation.

NK92 cells (ATCC CRL-2407) expressing CD16 were cultured in alphaMEM (Gibco; Cat# 12000022) supplemented with 12.5% FBS (Hyclone SH30071.03), 12.5% horse serum (Hyclone; Cat#
SH30074.03), 1.5g/L sodium bicarbonate (Fisher Sci; Cat# S-233-500), 0.02 mM Folic acid (Alfa
Aesar; Cat# J62937), 0.2 mM Inositol (MP Biomedical; Cat# 194688), 0.1 mM Betamercaptoethanol (Gibco; Cat# 21985-023), 100 U/ml recombinant IL-2 (StemCell; Cat# 78036.3).
Recombinant SARS-CoV-2 spike was coated onto MaxiSorp 96-well plates (Thermo Scientific

769 Cat# 442404) at 300 ng/well at 4°C overnight. Wells were washed with PBS and blocked with 5% 770 BSA. Serum samples diluted 1:50 in PBS were added to the wells and incubated for 2 h at 37 °C. 771 Unbound antibodies were removed by washing wells with PBS. NK92 cells in complete alphaMEM 772 culture medium were added at 5 x 10^4 cells/well in the presence of 4 µg/ml brefeldin A (Biolegend 773 Cat# 420601), 5 µg/ml GolgiStop (BD Biosciences Cat# 554724) and 0.15µg of anti-CD107a 774 antibody (Clone H4A3 PE-Cy7, Biolegend Cat# 328618) for 5 hours at 37°C. Cells were stained 775 for surface expression of CD16 (Clone 3G8 Pacific Blue, Biolegend Cat# 302032) and CD56 776 (clone 5.1H11 AlexaFluor488 Biolegend, Cat# 362518). Cells were fixed and permeabilized with 777 Fix/Perm (Biolegend Cat# 421002) according to the manufacturer's instructions and stained for 778 intracellular IFNg (Clone B27 PE, Biolegend Cat# 506507), and TNFa (clone Mab11 APC, 779 Biolegend Cat# 502912). Cells were analyzed on a Cytek Aurora spectral flow cytometer.

780

781 Antibody-dependent neutrophil phagocytosis (ADNP)

782 Protocol was adapted from [72]. Recombinant biotinylated SARS-CoV-2 spike protein was 783 coupled to Neutravidin fluorescent beads (LifeTechnologies). Serum samples diluted 1:100 in 784 culture medium were incubated with spike-coated beads for 2h at 37°C. Freshly isolated white 785 blood cells from human donor peripheral blood (5x104 cells/well) were added to wells and 786 incubated for 1 hour at 37°C. Cells were stained for CD66b (Clone G10F5; Biolegend), CD3 787 (Clone UCHT1; BD Biosciences), and CD14 (Clone MiP9; BD Biosciences), fixed with 4% 788 paraformaldehyde, and analyzed by flow cytometry on a Cytek Aurora spectral flow cytometer. 789 Neutrophils were defined as SSC-Ahigh CD66b+, CD3neg, CD14neg. A phagocytic score was 790 determined using the following formula: (percentage of bead+ cells)*(geometric mean fluorescent 791 intensity (gMFI) of red bead+ cells)/10,000.

792

793 Antibody-dependent cellular phagocytosis by human monocytes (ADCP)

794 Protocol was adapted from [73]. THP-1 monocytes were maintained in RPMI-1640 supplemented 795 10% FBS, penicillin/streptomycin (Gibco Cat#15070063), L-glutamine, with and b-796 mercaptoethanol. Recombinant SARS-CoV-2 spike-coated beads were generated as described 797 for ADNP. Serum samples were diluted in a five-fold dilution curve in THP-1 culture medium 798 (1:2500, 1:12500, 1:62500) and incubated with spike-coated beads for 2 h at 37 °C. Unbound antibodies were removed by centrifugation before adding THP-1 cells at 2.5x10⁴ cells/well. Cells 799 800 were fixed with 4% paraformaldehyde and analyzed by flow cytometry for uptake of fluorescent 801 beads on a Cytek Aurora spectral flow cytometer. A phagocytic score was determined as 802 described above, and the areas under the curve for the three dilutions were calculated.

803

804 Antibody-mediated complement deposition (ADCD)

Protocol was adapted from [74]. Recombinant SARS-CoV-2 spike-coated beads were generated as described for ADNP. Serum samples were diluted in culture medium 1:10 and incubated with spike-coated beads for 2 hours at 37 °C. Unbound antibodies were removed by centrifugation prior to the addition of reconstituted guinea pig complement (Cedarlane Labs CL4051) diluted in veronal buffer supplemented with calcium and magnesium (Boston Bioproducts) for 20 min at 37°C. Beads were washed with PBS containing 15 mM EDTA and stained with an FITCconjugated anti-guinea pig C3 antibody (MP Biomedicals). C3 deposition onto beads was

analyzed by flow cytometry on a Cytek Aurora spectral flow cytometer. The gMFI of FITC of all

- 813 beads was measured.
- 814

815 **PBMC restimulation and culture**

816 6-7.2x10⁵ PBMCs were cultured for 24 h in the presence of Spike Glycoprotein 0.2µg/well (BEI, 817 NR-52308, produced under HHSN272201400008C and obtained through BEI Resources, NIAID, 818 NIH: Spike Glycoprotein (stabilized) from SARS-Related Coronavirus 2, Wuhan-Hu-1 with C-819 Terminal Histidine Tag, Recombinant from Baculovirus), and SARS-CoV-2 specific mega pools 820 at 0.2 µg/well including PepTivator SARS-CoV-2 Prot S (Miltinyi - 130-126-700), SARS-CoV-2 821 Prot_M (130-126-702), SARS-CoV-2 Prot_N (130-126-699) in 96-well U bottom tissue culture 822 plate (CytoOne CC7672-7596) in 200 µl RPMI-1640 with 10% FBS. Media was used as a negative 823 control. Supernatants were harvested at 24 h post-stimulation for multiplex cytokines detection 824 and stored at -80°C.

825

826 Activation-induced marker (AIM) staining & detection

827 Restimulated cells from above were pelleted and stained with Fixable Viability Dye eFluor™ 780 828 in DPBS (eBioscience) for 30 minutes at 4C in the dark, then washed and resuspended in 50 829 ul with an antibody cocktail in Brilliant Stain Buffer (Biosciences) [75, 76] for 30 minutes at 4C. 830 Cells were then washed with flow buffer (500 ml 1x PBS ThermoFisher 20012-027, 5 g BSA 831 Roche 10735078001, 0.5 g Sodium Azide Sigma S2002) and fixed for 20 minutes at 4C with 10% formalin (polyScience 04018-1), Following fixation, cells were washed and resuspended in 832 833 200 µl flow buffers. All samples were acquired on a BD LSRFortessa. A list of antibodies used in 834 this panel can be found table 1 below:

835

Table 1. Cellular antibodies used for AIM assay.							
<u>Stain</u>	Source	Catalog number	Antibody				
FITC	BioLegend	356914	anti-CD185				
AF700	BioLegend	344724	anti-CD8				
PE-Cy7	BioLegend	300914	anti-CD8a				
BV510	BioLegend	317444	anti-CD4				
FITC	BioLegend	310904	anti-CD69				
APC-Cy7	BioLegend	366614	anti-CD33				
PerCP-Cy5.5	Invitrogen	45-0338-42	anti-CD33				
PE	BioLegend	350004	anti-CD134				
PE-Cy7	BioLegend	300420	anti-CD3				
eFlour450	Invitrogen	48-0037-42	anti-CD3				
APC	BioLegend	309810	anti-CD137				
APC-CY7	ThermoFisher	65-0865-14	Live/Dead				
Note. All samples were acquired on a BD LSRFortessa.							

836

837 Cytokine testing

838 Cytokine test kits were used to measure cytokine levels in supernatant fluids from restimulated 839 PBMC cultures according to manufacturers' protocol. Kit types included Bio-plex Pro Human 840 Cytokine 17-plex (Biorad) or custom human (Biorad Bio-plex IFN-y, IL-2, IL-5, IL-6, TNFa; 841 Biolegend Legendplex Perforin, and Granzyme B, BAFF, MIP-1β, IL-4, IL-10, IL-13, IL-15, IL-842 17A). Samples tested with the Legend-plex kit were reanalyzed with the standards for each 843 cytokine with the best range. Results from comparing cytokine levels in stimulated and mock 844 stimulated cultures were expressed as fold change. This calculation reduced batch effects among 845 experiments. Values of zero from bio-plex kits were replaced with 0.1 or 1 (TNF- α only) or for 846 Legend-plex kits with 0.1 or 1 (MIP-1 β and BAFF only).

847

848 Statistical Analysis

849 Continuous data were expressed as means and standard deviations, medians and ranges, or 850 medians and interguartile ranges. Categorical data were presented as frequencies and 851 percentages. General comparisons among continuous predictors were performed using Krusal-852 Wallis test with Dunn's post-tests for pairwise comparisons. General comparisons for categorical 853 responses were performed using Pearson's chi-square test (or Fisher's Exact test where the 854 assumption of a normal approximation to the binomial distribution was not justified). Pairwise 855 comparisons for categorical responses were performed using logistic regression model contrasts. 856 Dimensionality reduction was performed using t-Distributed Stochastic Neighbor Embedding [t-857 SNE] and Uniform Manifold Approximation and Projection [UMAP]) using the JMP Embedding 858 Add On [77]. Feature selection using lasso regression was performed in JMP Pro 16. Lasso-859 selected features were used in a partial least square regression analysis with a leave-one-out 860 validation method in JMP Pro 16. Features with a variable importance in projection score (VIP) 861 >0.8 were used to generate a principal component analysis in JMP Pro 16. Data management 862 and statistical analyses were carried out using the FloJo (version 10 Becton, Dickinson and 863 Company, Ashland, OR), R (Version 4.1.2, R Foundation for Statistical Computing, Vienna, 864 Austria) GraphPad Prism (version 9.0.0, GraphPad Software, San Diego, CA), JMP (version 865 16.2.0, SAS Institute, Inc., Cary, NC), and SAS (version 9.4, SAS Institute, Inc., Cary, NC). The 866 type I error threshold was set at 5%.

867

868 Data imputation for dimension reduction analyses

Data were singly imputed for tSNE and UMAP analyses using mean imputation for continuous
variables and mode imputation for categorical variables. All imputed data were required to have
at least 60% of non-missing cell values. Those variables not including at least 60% of observed
data were excluded from the dimension reduction analyses.

- 873
- 874
- 875

876 **REFERENCES**877

- 8781.Kojima, N. and J.D. Klausner, Protective immunity after recovery from SARS-CoV-2879infection. Lancet Infect Dis, 2022. 22(1): p. 12-14.
- Bange, E.M., et al., CD8(+) T cells contribute to survival in patients with COVID-19 and
 hematologic cancer. Nat Med, 2021. 27(7): p. 1280-1289.

- 882 3. Cohen, B., et al., COVID-19 infection in 10 common variable immunodeficiency patients in
 883 New York City. J Allergy Clin Immunol Pract, 2021. 9(1): p. 504-507 e1.
- 4. Grifoni, A., et al., *Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.* Cell, 2020. **181**(7): p. 1489-1501 e15.
- 8865.Le Bert, N., et al., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and887uninfected controls. Nature, 2020. 584(7821): p. 457-462.
- 8886.Israelow, B., et al., Adaptive immune determinants of viral clearance and protection in889mouse models of SARS-CoV-2. Sci Immunol, 2021. 6(64): p. eabl4509.
- McMahan, K., et al., Correlates of protection against SARS-CoV-2 in rhesus macaques.
 Nature, 2021. 590(7847): p. 630-634.
- 8. Yang, H.S., et al., Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw
 893 Open, 2021. 4(3): p. e214302.
- 8949.Bajaj, V., et al., Aging, Immunity, and COVID-19: How Age Influences the Host Immune895Response to Coronavirus Infections? Front Physiol, 2020. 11: p. 571416.
- 89610.Bartsch, Y.C., et al., Humoral signatures of protective and pathological SARS-CoV-2897infection in children. Nat Med, 2021. 27(3): p. 454-462.
- 89811.Chou, J., P.G. Thomas, and A.G. Randolph, Immunology of SARS-CoV-2 infection in899children. Nat Immunol, 2022. 23(2): p. 177-185.
- 900 12. Cohen, C.A., et al., SARS-CoV-2 specific T cell responses are lower in children and increase
 901 with age and time after infection. Nat Commun, 2021. 12(1): p. 4678.
- Rydyznski Moderbacher, C., et al., Antigen-Specific Adaptive Immunity to SARS-CoV-2 in
 Acute COVID-19 and Associations with Age and Disease Severity. Cell, 2020. 183(4): p.
 904 996-1012 e19.
- 90514.Weisberg, S.P., et al., Distinct antibody responses to SARS-CoV-2 in children and adults906across the COVID-19 clinical spectrum. Nat Immunol, 2021. 22(1): p. 25-31.
- 90715.Garrido, C., et al., Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable908neutralizing antibody responses in children and adolescents. JCI Insight, 2021. 6(17).
- 90916.Klein, S.L., et al., Sex, age, and hospitalization drive antibody responses in a COVID-19910convalescent plasma donor population. J Clin Invest, 2020. 130(11): p. 6141-6150.
- 91117.Long, Q.X., et al., Clinical and immunological assessment of asymptomatic SARS-CoV-2912infections. Nature Medicine 2020.
- 91318.Wang, P., et al., SARS-CoV-2 neutralizing antibody responses are more robust in patients914with severe disease. Emerg Microbes Infect, 2020. **9**(1): p. 2091-2093.
- 915 19. Bergwerk, M., et al., *Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.*916 N Engl J Med, 2021. **385**(16): p. 1474-1484.
- 917 20. Cromer, D., et al., *Neutralising antibody titres as predictors of protection against SARS-*918 *CoV-2 variants and the impact of boosting: a meta-analysis.* Lancet Microbe, 2022. 3(1):
 919 p. e52-e61.
- Schoury, D.S., et al., Neutralizing antibody levels are highly predictive of immune protection
 from symptomatic SARS-CoV-2 infection. Nat Med, 2021. 27(7): p. 1205-1211.
- 92222.Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity, in CDC923COVID-19 Science Briefs. 2020: Atlanta (GA).
- 23. Zohar, T., et al., Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
 25. Mortality. Cell, 2020. 183(6): p. 1508-1519 e12.

926	24.	Le Bert, N., et al., Highly functional virus-specific cellular immune response in
927		asymptomatic SARS-CoV-2 infection. J Exp Med, 2021. 218 (5).
928	25.	Liu, W.J., et al., T-cell immunity of SARS-CoV: Implications for vaccine development against
929		MERS-CoV. Antiviral Res, 2017. 137: p. 82-92.
930	26.	Moss, P., The T cell immune response against SARS-CoV-2. Nat Immunol, 2022. 23(2): p.
931		186-193.
932	27.	Jung, J.H., et al., SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent
933		patients for 10 months with successful development of stem cell-like memory T cells. Nat
934		Commun, 2021. 12 (1): p. 4043.
935	28.	Peng, Y., et al., Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-
936		2 in UK convalescent individuals following COVID-19. Nat Immunol, 2020. 21(11): p. 1336-
937		1345.
938	29.	Mok, C.K.P., et al., T-cell responses to MERS coronavirus infection in people with
939		occupational exposure to dromedary camels in Nigeria: an observational cohort study.
940		Lancet Infect Dis, 2021. 21 (3): p. 385-395.
941	30.	Bergamaschi, L., et al., Longitudinal analysis reveals that delayed bystander CD8+ T cell
942		activation and early immune pathology distinguish severe COVID-19 from mild disease.
943		Immunity, 2021. 54 (6): p. 1257-1275 e8.
944	31.	Notarbartolo, S., et al., Integrated longitudinal immunophenotypic, transcriptional and
945		repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol, 2021.
946		6 (62).
947	32.	Nelson, C.E., et al., Mild SARS-CoV-2 infection in rhesus macaques is associated with viral
948		control prior to antigen-specific T cell responses in tissues. Sci Immunol, 2022: p.
949		eabo0535.
950	33.	Huang, Z., et al., Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-
951		<i>2 infection.</i> J Clin Invest, 2021. 131 (7).
952	34.	Huang, Z., et al., Ultra-sensitive and high-throughput CRISPR-p owered COVID-19
953		<i>diagnosis.</i> Biosens Bioelectron, 2020. 164 : p. 112316.
954	35.	Bergamaschi, C., et al., Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature
955		associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine
956		<i>recipients.</i> Cell Rep, 2021. 36 (6): p. 109504.
957	36.	Pegu, A., et al., Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2
958		<i>variants.</i> Science, 2021. 373 (6561): p. 1372-1377.
959	37.	Levin, E.G., et al., Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over
960		<i>6 Months.</i> N Engl J Med, 2021. 385 (24): p. e84.
961	38.	Rodda, L.B., et al., Functional SARS-CoV-2-Specific Immune Memory Persists after Mild
962		<i>COVID-19.</i> Cell, 2021. 184 (1): p. 169-183 e17.
963	39.	Zeng, F., et al., Over 1-year duration and age difference of SARS-CoV-2 antibodies in
964		<i>convalescent COVID-19 patients.</i> J Med Virol, 2021. 93 (12): p. 6506-6511.
965	40.	Lau, E.H.Y., et al., Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun,
966		2021. 12 (1): p. 63.
967	41.	Wu, J., et al., SARS-CoV-2 infection induces sustained humoral immune responses in
968		convalescent patients following symptomatic COVID-19. Nat Commun, 2021. 12(1): p.
969		1813.


- 970 42. Jin, C.C., et al., *Correlation between viral RNA shedding and serum antibodies in individuals*971 *with coronavirus disease 2019.* Clin Microbiol Infect, 2020. 26(9): p. 1280-1282.
- 43. Lofano, G., et al., Antigen-specific antibody Fc glycosylation enhances humoral immunity
 via the recruitment of complement. Sci Immunol, 2018. 3(26).
- 974 44. Ouchida, R., et al., *Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival,*975 and humoral immune responses. Proc Natl Acad Sci U S A, 2012. **109**(40): p. E2699-706.
- 976 45. Pusnik, J., et al., *Memory B cells targeting SARS-CoV-2 spike protein and their dependence*977 on CD4(+) T cell help. Cell Rep, 2021. **35**(13): p. 109320.
- 978 46. Juno, J.A., et al., *Humoral and circulating follicular helper T cell responses in recovered*979 *patients with COVID-19.* Nat Med, 2020. 26(9): p. 1428-1434.
- 47. Kared, H., et al., SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19
 981 individuals. J Clin Invest, 2021. 131(5).
- 982 48. Oberhardt, V., et al., *Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA* 983 vaccine. Nature, 2021. **597**(7875): p. 268-273.
- 98449.Larsen, M.D., et al., Afucosylated IgG characterizes enveloped viral responses and985correlates with COVID-19 severity. Science, 2021. **371**(6532).
- 98650.Hoepel, W., et al., High titers and low fucosylation of early human anti-SARS-CoV-2 IgG987promote inflammation by alveolar macrophages. Sci Transl Med, 2021. 13(596).
- 98851.Chakraborty, S., et al., Early non-neutralizing, afucosylated antibody responses are989associated with COVID-19 severity. Sci Transl Med, 2022. 14(635): p. eabm7853.
- S2. Chakraborty, S., et al., *Proinflammatory IgG Fc structures in patients with severe COVID- 19.* Nat Immunol, 2021. **22**(1): p. 67-73.
- Sterlin, D., et al., *IgA dominates the early neutralizing antibody response to SARS-CoV-2.*Sci Transl Med, 2021. **13**(577).
- 994 54. Wang, Z., et al., *Enhanced SARS-CoV-2 neutralization by dimeric IgA*. Sci Transl Med, 2021.
 995 **13**(577).
- 99655.Azzi, L., et al., Mucosal immune response in BNT162b2 COVID-19 vaccine recipients.997EBioMedicine, 2022. **75**: p. 103788.
- 99856.Selva, K.J., et al., Systems serology detects functionally distinct coronavirus antibody999features in children and elderly. Nat Commun, 2021. 12(1): p. 2037.
- 100057.Crowley, A.R., et al., Boosting of cross-reactive antibodies to endemic coronaviruses by1001SARS-CoV-2 infection but not vaccination with stabilized spike. Elife, 2022. 11.
- 100258.Kaplonek, P., et al., Early cross-coronavirus reactive signatures of humoral immunity1003against COVID-19. Sci Immunol, 2021. 6(64): p. eabj2901.
- 1004 59. Lin, C.Y., et al., *Pre-existing humoral immunity to human common cold coronaviruses*1005 *negatively impacts the protective SARS-CoV-2 antibody response*. Cell Host Microbe, 2022.
 1006 **30**(1): p. 83-96 e4.
- 100760.Tarke, A., et al., Comprehensive analysis of T cell immunodominance and1008immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med, 2021. 2(2):1009p. 100204.
- 101061.Painter, M.M., et al., Rapid induction of antigen-specific CD4(+) T cells is associated with1011coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity,10122021. 54(9): p. 2133-2142 e3.

- 101362.Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 20211014Case Definition.2021February21,2022];Availablefrom:1015https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.
- 101663.Baj, J., et al., COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms:1017The Current State of Knowledge. J Clin Med, 2020. 9(6).
- 101864.Mallone, R., et al., Isolation and preservation of peripheral blood mononuclear cells for1019analysis of islet antigen-reactive T cell responses: position statement of the T-Cell1020Workshop Committee of the Immunology of Diabetes Society. Clinical and Experimental1021Immunology, 2010. 163(1): p. 33-49.
- 1022 65. Nilsson, C., et al., Optimal blood mononuclear cell isolation procedures for gamma
 1023 interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.
 1024 Clin Vaccine Immunol, 2008. 15(4): p. 585-9.
- 1025 66. Hastie, K.M., et al., *Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies:* 1026 A global consortium study. Science, 2021. **374**(6566): p. 472-478.
- 1027 67. Hsieh, C.L., et al., *Structure-based design of prefusion-stabilized SARS-CoV-2 spikes*.
 1028 Science, 2020. **369**(6510): p. 1501-1505.
- 102968.Gordon, D.E., et al., A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug1030Targets and Potential Drug-Repurposing. bioRxiv, 2020.
- 103169.Zhang, L., et al., SARS-CoV-2 spike-protein D614G mutation increases virion spike density1032and infectivity. Nat Commun, 2020. 11(1): p. 6013.
- 103370.Weissman, D., et al., D614G Spike Mutation Increases SARS CoV-2 Susceptibility to1034Neutralization. Cell Host Microbe, 2021. 29(1): p. 23-31.e4.
- 1035 71. Naldini, L., et al., *Efficient transfer, integration, and sustained long-term expression of the*1036 *transgene in adult rat brains injected with a lentiviral vector.* Proc Natl Acad Sci U S A,
 1037 1996. **93**(21): p. 11382-8.
- 103872.Karsten, C.B., et al., A versatile high-throughput assay to characterize antibody-mediated1039neutrophil phagocytosis. J Immunol Methods, 2019. 471: p. 46-56.
- 104073.Ackerman, M.E., et al., A robust, high-throughput assay to determine the phagocytic1041activity of clinical antibody samples. J Immunol Methods, 2011. **366**(1-2): p. 8-19.
- 1042 74. Fischinger, S., et al., A high-throughput, bead-based, antigen-specific assay to assess the
 1043 ability of antibodies to induce complement activation. J Immunol Methods, 2019. 473: p.
 1044 112630.
- 1045 75. McKinnon, K.M., *Multiparameter Conventional Flow Cytometry*. Methods Mol Biol, 2018.
 1046 1678: p. 139-150.
- 104776.Acosta, J.R., et al., Increased fat cell size: a major phenotype of subcutaneous white1048adipose tissue in non-obese individuals with type 2 diabetes. Diabetologia, 2016. 59(3): p.1049560-570.
- 1050 77. JMP. Data visualization with t-SNE and UMAP. 2020 March 14, 2022]; Available from:
 1051 <u>https://community.jmp.com/t5/JMP-Add-Ins/Data-visualization-with-t-SNE-and-</u>
 1052 UMAP/ta-p/177969.
- 1053

Table 1. Composition of study cohort by SARS-CoV-2 infection status.


		SARS-CoV	-2 infected	SAR	S-CoV-2 non- infected	1	Total		I
Demographic Characteristics	Categories	n=67		n=24		n=91		P value	
Dates of first visit Households, No.		6/12/2020 - 2/27/21 35		6/12/2020 - 12/15/20 12		6/12/2020 - 2/27/21 45		Pearson chi square 0.0006	Missing values
Age, Median (Range)		31	4 - 79	34	1 - 69	31	1 - 79	0.0147	
	<18 years, No. (%)	7	10.4%	7	29.2%	14	15.4%		
	18-50 years, No. (%)	37	55.2%	15	20.8%	52	57.1%	0.014	
	51+ years, No. (%)	23	34.3%	2	8.3%	25	27.5%		
Female No. (%)	, , , , ,	47	70.1%	12	50.0%	59	64.8%	0.0761	
	White	56	83.6%	21	87.5%	77	84.6%		
Ethnicity, No. (%)	Other	11	16.4%	3	12.5%	14	15.4%	0.851	
Body Mass Index Ca	tegory, No. (%)								
	Underweight	3	4.5%	2	8.7%	5	5.6%		
	Healthy Weight	39	59.1%	8	34.8%	47	52.8%	1	
	Overweight	15	22.7%	8	34.8%	23	25.8%	0.2506	2
	Obese	9	13.6%	5	21.7%	14	15.7%	-	
Smoking, No. (%)		9	13.6%	0	0.0%	9	10.0%	0.0565	1
Has a chronic condit	ions, No. (%)	19	30.6%	7	31.8%	26	31.0%	0.9186	7
	Hypertension, No (%)	6	9.7%	2	9.1%	8	9.5%	0.9358	7
	Asthma, No. (%)	3	4.8%	2	9.1%	5	6.0%	0.4689	7
	High cholesterol, No. (%)	9	14.5%	1	4.5%	10	11.9%	0.2147	7
COVID specific detai	• - · · ·								
Reported symptoms with illness, No. (%)		58	86.6%	14	58.3%	72	79.1%	0.0035	
visited the ER for su	spected illness, No. (%)	9	13.4%	1	4.2%	10	11.0%	0.213	
tested SARS-CoV-2+	(PCR self), No. (%)	42	62.7%	0	0.0%	42	46.2%	<0.0001	
tested SARS-CoV-2+ (PCR household), No. (%)		53	79.1%	0	0.0%	53	58.2%	<0.0001	
Plasma viral RNA detected, No. (%)		11	16%	0	0%	0	12%	0.0343	
Serostatus, No. (%)	anti-S positive	54	80.6%	0	0.0%	54	59.3%	<0.0001	
	anti-S indeterminant	6	9.0%	3	12.5%	9	9.9%		
	anti-S negative	7	10.4%	21	87.5%	28	30.8%		
	anti-N positive	32	47.8%	0	0.0%	32	35.2%	<0.0001	
	anti-N indeterminant	28	41.8%	3	12.5%	31	34.1%		
	anti-N negative	7	10.4%	21	87.5%	28	30.8%		
met COVID-19 case definition		51	76%	0	0%	51	56%	<0.0001	
mean days from possible exposure (range)		93	(23-252)	133	(10-289)	104	(10-289)	0.1119	

Figure 1



Α.

Figure 2







Figure S2










Figure 3











10-


0.1



infection








Spike BAFF

÷

۵


100 200 days





6


0














100-

10

1

0.1




3.

2-

1.

0-



Spike TNF-a

0.0779

÷

3

2

1

0-

800


8


Th1: Npep

÷

0.5155


10000








÷

Th1: Mpep










В.

Figure 4



Α.

Figure 5






Figure S6



Cluster 1



F.


ANAM . Spike IL-2: B lgG1: Th1: CD4 Spike Spike AIM: Sp D ${\scriptstyle \bigtriangleup}^{\widehat{\Delta}}$ Δ //// MARKANNA AND N KANKA A A 5 Δ Δ AA AMMAA AMMAA Λ Δ Δ Δ MA \wedge 10/100 Neutralization ADNP ADCP ADNKA: **TNFa**

Cluster 2

ADCD

ADNKA:

Veutralizatio







Figure 6






g


<90 days post-vaccination responses


Figure S7






correlations to post-vaccination neutralization titers (all samples or >90 days)









C.

visit 1 post-infection/pre-vaccination

